The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Cytokines in immunogenic cell death: Applications for cancer immunotherapy
Open accessAbstract
Despite advances in treatments like chemotherapy and radiotherapy, metastatic cancer remains a leading cause of death for cancer patients. While many chemotherapeutic agents can efficiently eliminate cancer cells, long-term protection against cancer is not achieved and many patients experience cancer recurrence. Mobilizing and stimulating the immune system against tumor cells is one of the most effective ways to protect against cancers that recur and/or metastasize. Activated tumor specific cytotoxic T lymphocytes (CTLs) can seek out and destroy metastatic tumor cells and reduce tumor lesions. Natural Killer (NK) cells are a front-line defense against drug-resistant tumors and can provide tumoricidal activity to enhance tumor immune surveillance. Cytokines like IFN-γ or TNF play a crucial role in creating an immunogenic microenvironment and therefore are key players in the fight against metastatic cancer. To this end, a group of anthracyclines or treatments like photodynamic therapy (PDT) exert their effects on cancer cells in a manner that activates the immune system. This process, known as immunogenic cell death (ICD), is characterized by the release of membrane-bound and soluble factors that boost the function of immune cells. This review will explore different types of ICD inducers, some in clinical trials, to demonstrate that optimizing the cytokine response brought about by treatments with ICD-inducing agents is central to promoting anti-cancer immunity that provides long-lasting protection against disease recurrence and metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., & Mori, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00611-0 · Cited by 4,039
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“When released from dying cancer cells, HMGB1 stimulates toll-like receptor (TLR) signaling, leading to protective immunity [13].”
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Schlesinger, M. J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38314-0 · Cited by 1,355
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Calreticulin: one protein, one gene, many functions
Michalak, M., Corbett, E. F., Mesaeli, N., Nakamura, K., & Opas, M. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3440281 · Cited by 830
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
Soesatyo, M. H. (2012) · Jurnal Teknosains · doi:10.22146/teknosains.5992 · Cited by 652
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
Loke, P., & Allison, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931259100 · Cited by 634
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy
Schmitt, E., Gehrmann, M., Brunet, M., Multhoff, G., & Garrido, C. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306167 · Cited by 573
Yang, H., Antoine, D. J., Andersson, U., & Tracey, K. J. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212662 · Cited by 542
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 492
The GCN2 eIF2α Kinase Is Required for Adaptation to Amino Acid Deprivation in Mice
Zhang, P., McGrath, B. C., Reinert, J., Olsen, D. S., Lei, L., Gill, S., Wek, S. A., Vattem, K. M., Wek, R. C., Kimball, S. R., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.19.6681-6688.2002 · Cited by 438
Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A. Q., Michaud, M., Mignot, G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003807 · Cited by 423
A review of the mammalian unfolded protein response
Chakrabarti, A., Chen, A. W., & Varner, J. D. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23282 · Cited by 409
Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., & Konishi, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0224 · Cited by 395
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
Calreticulin: non‐endoplasmic reticulum functions in physiology and disease
Gold, L. I., Eggleton, P., Sweetwyne, M. T., Van Duyn, L. B., Greives, M. R., Naylor, S., Michalak, M., & Murphy‐Ullrich, J. E. (2010) · The FASEB Journal · doi:10.1096/fj.09-145482 · Cited by 382
Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
Inoue, H., & Tani, K. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.84 · Cited by 347
ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death
Garg, A. D., Dudek, A. M., Ferreira, G. B., Verfaillie, T., Vandenabeele, P., Krysko, D. V., Mathieu, C., & Agostinis, P. (2013) · Autophagy · doi:10.4161/auto.25399 · Cited by 305
Wan, S., Pestka, S., Jubin, R. G., Lyu, Y. L., Tsai, Y.-C., & Liu, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032542 · Cited by 295
IL-6 involvement in epithelial cancers
Schafer, Z. T., & Brugge, J. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci34237 · Cited by 269
Immune Evasion Strategies of Glioblastoma
Razavi, S.-M., Lee, K. E., Jin, B. E., Aujla, P. S., Gholamin, S., & Li, G. (2016) · Frontiers in Surgery · doi:10.3389/fsurg.2016.00011 · Cited by 262
Zhao, X., Yang, K., Zhao, R., Ji, T., Wang, X., Yang, X., Zhang, Y., Cheng, K., Liu, S., Hao, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.032 · Cited by 256
Measles virus causes immunogenic cell death in human melanoma
Donnelly, O. G., Errington-Mais, F., Steele, L., Hadac, E., Jennings, V, Scott, K., Peach, H., Phillips, R. M., Bond, J., Pandha, H., et al. (2013) · Gene Therapy · doi:10.1038/gt.2011.205 · Cited by 187
Duewell, P., Steger, A., Lohr, H., Bourhis, H., Hoelz, H., Kirchleitner, S. V., Stieg, M. R., Grassmann, S., Kobold, S., Siveke, J. T., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.96 · Cited by 179
Rios-Doria, J., Durham, N., Wetzel, L., Rothstein, R., Chesebrough, J., Holoweckyj, N., Zhao, W., Leow, C. C., & Hollingsworth, R. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.004 · Cited by 174
High hydrostatic pressure induces immunogenic cell death in human tumor cells
Fucikova, J., Moserova, I., Truxova, I., Hermanova, I., Vancurova, I., Partlova, S., Fialova, A., Sojka, L., Cartron, P., Houska, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28766 · Cited by 170
Dispenzieri, A. A., Tong, C., LaPlant, B. R., Lacy, M. Q., Laumann, K. M., Dingli, D., Zhou, Y., Federspiel, M. J., Gertz, M. A., Hayman, S. R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.120 · Cited by 170
Geletneky, K., Huesing, J., Rommelaere, J., Schlehofer, J. R., Leuchs, B., Dahm, M., Krebs, O., Doeberitz, M. V. K., Huber, B., & Hajda, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-99 · Cited by 159
Ross, M. E., & Caligiuri, M. A. (1997) · Blood · doi:10.1182/blood.v89.3.910 · Cited by 153
Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage
Dewaele, M., Martinet, W., Rubio, N., Verfaillie, T., de Witte, P. A. M., Piette, J. G., & Agostinis, P. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01118.x · Cited by 146
Immunity and Immune Suppression in Human Ovarian Cancer
Preston, C. C., Goode, E. L., Hartmann, L. C., Kalli, K. R., & Knutson, K. L. (2011) · Immunotherapy · doi:10.2217/imt.11.20 · Cited by 144
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
Horton, T. M., Gannavarapu, A., Blaney, S. M., D’Argenio, D. Z., Plon, S. E., & Berg, S. L. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0135-z · Cited by 139
Autophagy modulation: a target for cancer treatment development
Duffy, A. P., Le, J., Sausville, E. A., & Emadi, A. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2637-z · Cited by 136
Fucikova, J., Truxova, I., Hensler, M., Becht, E., Kasikova, L., Moserova, I., Vosahlikova, S., Klouckova, J., Church, S. E., Cremer, I., et al. (2016) · Blood · doi:10.1182/blood-2016-08-731737 · Cited by 135 · cited 1×
“Studies to improve the ICD-inducing capacity of known agents and identification of new agents are needed as well as elucidating the importance of ICD markers, like CRT, as prognostic indicators of immune cell activity [64].”
Anticancer activity of cardiac glycosides
Kepp, O., Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Sukkurwala, A. Q., Michaud, M., Galluzzi, L., Zitvogel, L., et al. (2012) · OncoImmunology · doi:10.4161/onci.21684 · Cited by 111
Dudek-Perić, A. M., Ferreira, G. B., Muchowicz, A., Wouters, J., Prada, N., Martin, S., Kiviluoto, S., Winiarska, M., Boon, L., Mathieu, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2089 · Cited by 104
Wang, R., Town, T., Gokarn, V., Flavell, R. A., & Chandawarkar, R. Y. (2006) · Journal of Surgical Research · doi:10.1016/j.jss.2006.06.003 · Cited by 100
Angelova, A. L., Grekova, S. P., Heller, A., Kuhlmann, O., Soyka, E., Giese, T., Aprahamian, M., Bour, G., Rüffer, S., Cziepluch, C., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03688-13 · Cited by 76
Kawano, M., Tanaka, K., Itonaga, I., Iwasaki, T., Miyazaki, M., Ikeda, S., & Tsumura, H. (2016) · Oncology Letters · doi:10.3892/ol.2016.4175 · Cited by 69
Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma
Tongu, M., Harashima, N., Yamada, T., Harada, T., & Harada, M. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0797-1 · Cited by 56
Hajda, J., Lehmann, M., Krebs, O., Kieser, M., Geletneky, K., Jäger, D., Dahm, M., Huber, B., Schöning, T., Sedlaczek, O., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3604-y · Cited by 46
Siew, Y.-Y., Neo, S.-Y., Yew, H.-C., Lim, S.-W., Ng, Y.-C., Lew, S.-M., Seetoh, W.-G., Seow, S.-V., & Koh, H. (2015) · International Immunology · doi:10.1093/intimm/dxv041 · Cited by 45
Inoue, S., Setoyama, Y., & Odaka, A. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1489 · Cited by 32
Hsu, F., Chen, T., Chuang, H., Chang, Y.-F., & Hwang, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6628 · Cited by 32
Park, S., Kim, J., Do, K. H., Park, J., Oh, C. G., Choi, H. J., Song, B. G., Lee, S. J., Kim, Y. S., & Moon, Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568717 · Cited by 28
Induction of immunogenic cell death by radiation-upregulated karyopherin alpha 2 in vitro
Song, K., Jung, S.-Y., Kang, S.-M., Kim, M., Ahn, J., Hwang, S., Lee, J., Lim, D., Nam, S. Y., & Song, J. Y. (2016) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2016.04.002 · Cited by 24
Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells
Manandhar, S., Lee, S., & Kwak, M. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-0511-z · Cited by 23
Multhoff, G. (2009) · International Journal of Hyperthermia · doi:10.1080/02656730902835672 · Cited by 21
Panzarini, E., Inguscio, V., Tenuzzo, B. A., & Dini, L. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213494552 · Cited by 12
Cited by
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Li, Z., Lai, X., Fu, S., Ren, L., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 680
Cancer treatment therapies: traditional to modern approaches to combat cancers
Kaur, R., Bhardwaj, A., & Gupta, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08809-3 · Cited by 561
Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 557
Photodynamic therapy in cancer treatment - an update review
Dos Santos, A. F., De Almeida, D. R. Q., Terra, L. F., Baptista, M. S., & Labriola, L. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.83 · Cited by 446
Metadata
- Authors
- Showalter, A., Limaye, A., Oyer, J. L., Igarashi, R., Kittipatarin, C., Copik, A. J., & Khaled, A. R.
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 97
- Pages
- 123-132
- ISSN
- 1043-4666 (ISSN-L)
- OpenAlex
- W2644529227
- Cited by
- 319
- References
- 63
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.